155 related articles for article (PubMed ID: 6765400)
21. Computerized in vivo research from the growth of urease-producing bacteria in the presence of antibiotics combined with propionhydroxamic acid.
Rizzo M; Nicoletti P; Bartoletti R; Luciani E
Contrib Nephrol; 1987; 58():219-21. PubMed ID: 3319403
[No Abstract] [Full Text] [Related]
22. The effect of acetohydroxamic acid on the induction of bacterial ureases.
Rosenstein I; Hamilton-Miller JM; Brumfitt W
Invest Urol; 1980 Sep; 18(2):112-4. PubMed ID: 6997229
[TBL] [Abstract][Full Text] [Related]
23. Prevention of infected urinary stones in rats by urease inhibitor: a new hydroxamic acid derivative.
Takeuchi H; Kobashi K; Yoshida O
Invest Urol; 1980 Sep; 18(2):102-5. PubMed ID: 6997228
[TBL] [Abstract][Full Text] [Related]
24. Role of urease in the formation of infection stones: comparison of ureases from different sources.
Rosenstein IJ; Hamilton-Miller JM; Brumfitt W
Infect Immun; 1981 Apr; 32(1):32-7. PubMed ID: 7012032
[TBL] [Abstract][Full Text] [Related]
25. Dissemination of Proteus mirabilis isolates harboring CTX-M-14 and CTX-M-3 beta-lactamases at 2 hospitals in Taiwan.
Wu LT; Wu HJ; Chung JG; Chuang YC; Cheng KC; Yu WL
Diagn Microbiol Infect Dis; 2006 Feb; 54(2):89-94. PubMed ID: 16406185
[TBL] [Abstract][Full Text] [Related]
26. Quantification of Urease Activity.
Richmond S; Yep A
Methods Mol Biol; 2019; 2021():85-96. PubMed ID: 31309498
[TBL] [Abstract][Full Text] [Related]
27. A small-molecular inhibitor against Proteus mirabilis urease to treat catheter-associated urinary tract infections.
Milo S; Heylen RA; Glancy J; Williams GT; Patenall BL; Hathaway HJ; Thet NT; Allinson SL; Laabei M; Jenkins ATA
Sci Rep; 2021 Feb; 11(1):3726. PubMed ID: 33580163
[TBL] [Abstract][Full Text] [Related]
28. Virulence determinants of uropathogenic Escherichia coli and Proteus mirabilis.
Mobley HL; Island MD; Massad G
Kidney Int Suppl; 1994 Nov; 47():S129-36. PubMed ID: 7869662
[TBL] [Abstract][Full Text] [Related]
29. Different binding specificities of P. mirabilis compared to E. coli.
Lomberg H; Larsson P; Leffler H; Svanborg-Edén C
Scand J Infect Dis Suppl; 1982; 33():37-42. PubMed ID: 6753134
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of urease activity in the urinary tract pathogens Staphylococcus saprophyticus and Proteus mirabilis by dimethylsulfoxide (DMSO).
Deutch CE
J Appl Microbiol; 2020 May; 128(5):1514-1523. PubMed ID: 31860153
[TBL] [Abstract][Full Text] [Related]
31. Inhibitor-based methods for detection of plasmid-mediated AmpC beta-lactamases in Klebsiella spp., Escherichia coli, and Proteus mirabilis.
Coudron PE
J Clin Microbiol; 2005 Aug; 43(8):4163-7. PubMed ID: 16081966
[TBL] [Abstract][Full Text] [Related]
32. A Rare Opportunist,
Learman BS; Brauer AL; Eaton KA; Armbruster CE
Infect Immun; 2019 Dec; 88(1):. PubMed ID: 31611275
[TBL] [Abstract][Full Text] [Related]
33. [Prevention of infected urinary stones by urease inhibitor. IV. Treatment of infection stones in rats by a new hydroxamic acid and cefalexin].
Takeuchi H; Tomoyoshi T; Okada Y; Yoshida O; Kobashi K
Hinyokika Kiyo; 1983 Mar; 29(3):297-302. PubMed ID: 6375315
[TBL] [Abstract][Full Text] [Related]
34. Whole-cell Proteus mirabilis urease inhibition by aminophosphinates for the control of struvite formation.
Grela E; Dziełak A; Szydłowska K; Mucha A; Kafarski P; Grabowiecka AM
J Med Microbiol; 2016 Oct; 65(10):1123-1129. PubMed ID: 27550502
[TBL] [Abstract][Full Text] [Related]
35. UreR, the transcriptional activator of the Proteus mirabilis urease gene cluster, is required for urease activity and virulence in experimental urinary tract infections.
Dattelbaum JD; Lockatell CV; Johnson DE; Mobley HL
Infect Immun; 2003 Feb; 71(2):1026-30. PubMed ID: 12540589
[TBL] [Abstract][Full Text] [Related]
36. Clinical epidemiology of ciprofloxacin-resistant Proteus mirabilis isolated from urine samples of hospitalised patients.
Saito R; Okugawa S; Kumita W; Sato K; Chida T; Okamura N; Moriya K; Koike K
Clin Microbiol Infect; 2007 Dec; 13(12):1204-6. PubMed ID: 17850340
[TBL] [Abstract][Full Text] [Related]
37. Papillary necrosis in vitro: a scanning electron microscopic comparison of escherichia coli and Proteus mirabilis infection.
Cohen MS; Davis CP; Baur PS; Warren MM
Scan Electron Microsc; 1981; (Pt 3):65-72. PubMed ID: 7036330
[TBL] [Abstract][Full Text] [Related]
38. Allicin from garlic inhibits the biofilm formation and urease activity of Proteus mirabilis in vitro.
Ranjbar-Omid M; Arzanlou M; Amani M; Shokri Al-Hashem SK; Amir Mozafari N; Peeri Doghaheh H
FEMS Microbiol Lett; 2015 May; 362(9):. PubMed ID: 25837813
[TBL] [Abstract][Full Text] [Related]
39. Preventive and therapeutic administration of an indigenous Lactobacillus sp. strain against Proteus mirabilis ascending urinary tract infection in a mouse model.
Fraga M; Scavone P; Zunino P
Antonie Van Leeuwenhoek; 2005 Jul; 88(1):25-34. PubMed ID: 15928974
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of urease by miscellaneous ions and compounds. Implications for the therapy of infection-induced urolithiasis.
Burr RG
Invest Urol; 1977 Sep; 15(2):180-2. PubMed ID: 903216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
